These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

503 related articles for article (PubMed ID: 29671861)

  • 1. P2Y12 antagonist ticagrelor inhibits the release of procoagulant extracellular vesicles from activated platelets.
    Gasecka A; Nieuwland R; van der Pol E; Hajji N; Ćwiek A; Pluta K; Konwerski M; Filipiak KJ
    Cardiol J; 2019; 26(6):782-789. PubMed ID: 29671861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic Inhibition of Both P2Y1 and P2Y12 Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis.
    Gremmel T; Yanachkov IB; Yanachkova MI; Wright GE; Wider J; Undyala VV; Michelson AD; Frelinger AL; Przyklenk K
    Arterioscler Thromb Vasc Biol; 2016 Mar; 36(3):501-9. PubMed ID: 26743169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized controlled trial protocol to investigate the antiplatelet therapy effect on extracellular vesicles (AFFECT EV) in acute myocardial infarction.
    Gasecka A; Nieuwland R; Budnik M; Dignat-George F; Eyileten C; Harrison P; Huczek Z; Kapłon-Cieślicka A; Lacroix R; Opolski G; Pluta K; van der Pol E; Postuła M; Leroyer A; Siljander P; Sturk A; Filipiak KJ
    Platelets; 2020; 31(1):26-32. PubMed ID: 30585111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incomplete reversibility of platelet inhibition following prolonged exposure to ticagrelor.
    Gerrits AJ; Jakubowski JA; Sugidachi A; Michelson AD; Frelinger AL
    J Thromb Haemost; 2017 May; 15(5):858-867. PubMed ID: 28092426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell Surface Platelet Tissue Factor Expression: Regulation by P2Y
    Brambilla M; Becchetti A; Rovati GE; Cosentino N; Conti M; Canzano P; Giesen PLA; Loffreda A; Bonomi A; Cattaneo M; De Candia E; Podda GM; Trabattoni D; Werba PJ; Campodonico J; Pinna C; Marenzi G; Tremoli E; Camera M
    Arterioscler Thromb Vasc Biol; 2023 Oct; 43(10):2042-2057. PubMed ID: 37589138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adenosine derived from ADP can contribute to inhibition of platelet aggregation in the presence of a P2Y12 antagonist.
    Iyú D; Glenn JR; White AE; Fox SC; Heptinstall S
    Arterioscler Thromb Vasc Biol; 2011 Feb; 31(2):416-22. PubMed ID: 21106949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of P2Y12 polymorphisms on platelet activity but not ex-vivo antiplatelet effect of ticagrelor in healthy Chinese male subjects.
    Li MP; Tang J; Wen ZP; Zhang YJ; Zhang W; Zhou HH; Zhang ZL; Chen XP
    Blood Coagul Fibrinolysis; 2015 Dec; 26(8):874-81. PubMed ID: 26083990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous Platelet P2Y12 and P2Y1 ADP Receptor Blockade: Are Two Better Than One?
    Vaduganathan M; Bhatt DL
    Arterioscler Thromb Vasc Biol; 2016 Mar; 36(3):427-8. PubMed ID: 26912743
    [No Abstract]   [Full Text] [Related]  

  • 9. The protease-activated receptor 4 Ala120Thr variant alters platelet responsiveness to low-dose thrombin and protease-activated receptor 4 desensitization, and is blocked by non-competitive P2Y
    Whitley MJ; Henke DM; Ghazi A; Nieman M; Stoller M; Simon LM; Chen E; Vesci J; Holinstat M; McKenzie SE; Shaw CA; Edelstein LC; Bray PF
    J Thromb Haemost; 2018 Dec; 16(12):2501-2514. PubMed ID: 30347494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamic interplay of the P2Y(1), P2Y(12), and TxA(2) pathways in platelets: the potential of triple antiplatelet therapy with P2Y(1) receptor antagonism.
    Oestreich JH; Ferraris SP; Steinhubl SR; Akers WS
    Thromb Res; 2013 Feb; 131(2):e64-70. PubMed ID: 23245937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SAR216471, an alternative to the use of currently available P2Y₁₂ receptor inhibitors?
    Delesque-Touchard N; Pflieger AM; Bonnet-Lignon S; Millet L; Salel V; Boldron C; Lassalle G; Herbert JM; Savi P; Bono F
    Thromb Res; 2014 Sep; 134(3):693-703. PubMed ID: 25064036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
    Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
    Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Competitive mode and site of interaction of ticagrelor at the human platelet P2Y12 -receptor.
    Hoffmann K; Lutz DA; Straßburger J; Baqi Y; Müller CE; von Kügelgen I
    J Thromb Haemost; 2014 Nov; 12(11):1898-905. PubMed ID: 25186974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ticagrelor inhibits platelet-tumor cell interactions and metastasis in human and murine breast cancer.
    Gareau AJ; Brien C; Gebremeskel S; Liwski RS; Johnston B; Bezuhly M
    Clin Exp Metastasis; 2018 Feb; 35(1-2):25-35. PubMed ID: 29322294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversibility of platelet P2Y12 inhibition by platelet supplementation: ex vivo and in vitro comparisons of prasugrel, clopidogrel and ticagrelor.
    Bertling A; Fender AC; Schüngel L; Rumpf M; Mergemeier K; Geißler G; Sibrowski W; Kelsch R; Waltenberger J; Jakubowski JA; Kehrel BE
    J Thromb Haemost; 2018 Jun; 16(6):1089-1098. PubMed ID: 29582544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet inhibition by P2Y
    Shih CC; Chan MV; Kirkby NS; Vojnovic I; Mitchell JA; Armstrong PC; Warner TD
    Br J Pharmacol; 2021 Dec; 178(23):4758-4771. PubMed ID: 34383973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenosine diphosphate (ADP)-induced thromboxane A(2) generation in human platelets requires coordinated signaling through integrin alpha(IIb)beta(3) and ADP receptors.
    Jin J; Quinton TM; Zhang J; Rittenhouse SE; Kunapuli SP
    Blood; 2002 Jan; 99(1):193-8. PubMed ID: 11756171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adenosine receptor agonists deepen the inhibition of platelet aggregation by P2Y
    Boncler M; Wzorek J; Wolska N; Polak D; Watala C; Rozalski M
    Vascul Pharmacol; 2019 Feb; 113():47-56. PubMed ID: 30471364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitory Effect of Flavonolignans on the P2Y12 Pathway in Blood Platelets.
    Bijak M; Szelenberger R; Dziedzic A; Saluk-Bijak J
    Molecules; 2018 Feb; 23(2):. PubMed ID: 29439388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostaglandin E1 potentiates the effects of P2Y12 blockade on ADP-mediated platelet aggregation in vitro: Insights using short thromboelastography.
    Khanna V; Armstrong PC; Warner TD; Curzen N
    Platelets; 2015; 26(7):689-92. PubMed ID: 25734957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.